
News|Videos|February 7, 2025
Strategies for Managing Cytopenias and Infection Prophylaxis with CAR-T Therapy
The conversation examines adverse events beyond CRS and neurotoxicities in CAR-T therapy, focusing on strategies for managing prolonged cytopenias, infection prophylaxis, and unique adverse events associated with ide-cel and cilta-cel.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Beyond CRS and neurotoxicities, are there other adverse events that require particular attention?
- How do you address prolonged cytopenias following CAR-T infusion?
- What is your approach to infection prophylaxis and management in these patients?
- Are there any distinct adverse events associated specifically with ide-cel or cilta-cel that clinicians should be aware of?
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves TTFields Device With Chemo in Pancreatic Cancer
2
Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates
3
FDA Approves Pembrolizumab Combination in Platinum-Resistant Ovarian Cancer
4
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers
5






































